PARP1 and ovarian cancer: Altogether, our results herein demonstrate the synergistic effects of the PARP inhibitors and the arsenic compound in HR-proficient ovarian cancer cells in vitro and xenograft tumors derived from HR-proficient ovarian cancer cells in vivo, which do not respond well to the PARP inhibitors alone.